-
1
-
-
84891669630
-
New and future drug development for gastroesophageal reflux disease
-
Maradey-Romero C, Fass R,. New and future drug development for gastroesophageal reflux disease. J Neurogastroenterol Motil 2014; 20: 6-16.
-
(2014)
J Neurogastroenterol Motil
, vol.20
, pp. 6-16
-
-
Maradey-Romero, C.1
Fass, R.2
-
2
-
-
84868017013
-
Burden of gastrointestinal disease in the United States: 2012 update
-
Peery AF, Dellon ES, Lund J, et al,. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012; 143: 1179-87.
-
(2012)
Gastroenterology
, vol.143
, pp. 1179-1187
-
-
Peery, A.F.1
Dellon, E.S.2
Lund, J.3
-
3
-
-
0030931230
-
Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted County, Minnesota
-
Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd,. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-56.
-
(1997)
Gastroenterology
, vol.112
, pp. 1448-1456
-
-
Locke, G.R.1
Talley, N.J.2
Fett, S.L.3
Zinsmeister, A.R.4
Melton, L.J.5
-
4
-
-
0030962574
-
Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis
-
Chiba N, De Gara CJ, Wilkinson JM, Hunt RH,. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810.
-
(1997)
Gastroenterology
, vol.112
, pp. 1798-1810
-
-
Chiba, N.1
De Gara, C.J.2
Wilkinson, J.M.3
Hunt, R.H.4
-
5
-
-
17644416461
-
Epidemiology of gastro-oesophageal reflux disease: A systematic review
-
Dent J, El-Serag HB, Wallander MA, Johansson S,. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005; 54: 710-7.
-
(2005)
Gut
, vol.54
, pp. 710-717
-
-
Dent, J.1
El-Serag, H.B.2
Wallander, M.A.3
Johansson, S.4
-
6
-
-
84899976398
-
Update on the epidemiology of gastro-oesophageal reflux disease: A systematic review
-
El-Serag HB, Sweet S, Winchester CC, Dent J,. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2014; 63: 871-80.
-
(2014)
Gut
, vol.63
, pp. 871-880
-
-
El-Serag, H.B.1
Sweet, S.2
Winchester, C.C.3
Dent, J.4
-
7
-
-
84886891001
-
Gastroesophageal reflux disease: Update on inflammation and symptom perception
-
Altomare A, Guarino MPL, Cocca S, Emerenziani S, Cicala M,. Gastroesophageal reflux disease: update on inflammation and symptom perception. World J Gastroenterol 2013; 19: 6523-8.
-
(2013)
World J Gastroenterol
, vol.19
, pp. 6523-6528
-
-
Altomare, A.1
Guarino, M.P.L.2
Cocca, S.3
Emerenziani, S.4
Cicala, M.5
-
8
-
-
0141539363
-
Short-term treatment of gastroesophageal reflux disease
-
van Pinxteren B, Numans ME, Lau J, et al,. Short-term treatment of gastroesophageal reflux disease. J Gen Intern Med 2003; 18: 755-63.
-
(2003)
J Gen Intern Med
, vol.18
, pp. 755-763
-
-
Van Pinxteren, B.1
Numans, M.E.2
Lau, J.3
-
9
-
-
84858699762
-
Alternative therapeutic approaches to chronic proton pump inhibitor treatment
-
Fass R,. Alternative therapeutic approaches to chronic proton pump inhibitor treatment. Clin Gastroenterol Hepatol 2012; 10: 338-45.
-
(2012)
Clin Gastroenterol Hepatol
, vol.10
, pp. 338-345
-
-
Fass, R.1
-
10
-
-
80054787732
-
Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438)
-
Shin JM, Inatomi N, Munson K, et al,. Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther 2011; 339: 412-20.
-
(2011)
J Pharmacol Exp Ther
, vol.339
, pp. 412-420
-
-
Shin, J.M.1
Inatomi, N.2
Munson, K.3
-
11
-
-
77957228369
-
1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases
-
Hori Y, Imanishi A, Matsukawa J, et al,. 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther 2010; 335: 231-8.
-
(2010)
J Pharmacol Exp Ther
, vol.335
, pp. 231-238
-
-
Hori, Y.1
Imanishi, A.2
Matsukawa, J.3
-
12
-
-
79953716223
-
A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands
-
Matsukawa J, Hori Y, Nishida H, et al,. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol 2011; 81: 1145-51.
-
(2011)
Biochem Pharmacol
, vol.81
, pp. 1145-1151
-
-
Matsukawa, J.1
Hori, Y.2
Nishida, H.3
-
13
-
-
79956193494
-
A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals
-
Hori Y, Matsukawa J, Takeuchi T, et al,. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther 2011; 337: 797-804.
-
(2011)
J Pharmacol Exp Ther
, vol.337
, pp. 797-804
-
-
Hori, Y.1
Matsukawa, J.2
Takeuchi, T.3
-
14
-
-
84989307721
-
Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese/non-Japanese subjects
-
Sakurai Y, Nishimura A, Kennedy G, et al,. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol 2015; 6: e94. doi: 10.1038/ctg.2015.18
-
(2015)
Clin Transl Gastroenterol
, vol.6
, pp. e94
-
-
Sakurai, Y.1
Nishimura, A.2
Kennedy, G.3
-
15
-
-
84964207179
-
Randomised clinical trial: Safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects
-
Jenkins H, Sakurai Y, Nishimura A, et al,. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 2015; 41: 636-48.
-
(2015)
Aliment Pharmacol Ther
, vol.41
, pp. 636-648
-
-
Jenkins, H.1
Sakurai, Y.2
Nishimura, A.3
-
16
-
-
84939568162
-
Randomised clinical trial: A dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. Lansoprazole for the treatment of erosive oesophagitis
-
Ashida K, Sakurai Y, Nishimura A, et al,. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther 2015; 42: 685-95.
-
(2015)
Aliment Pharmacol Ther
, vol.42
, pp. 685-695
-
-
Ashida, K.1
Sakurai, Y.2
Nishimura, A.3
-
17
-
-
36549032595
-
A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis
-
Kahrilas PJ, Dent J, Lauritsen K, et al,. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 2007; 5: 1385-91.
-
(2007)
Clin Gastroenterol Hepatol
, vol.5
, pp. 1385-1391
-
-
Kahrilas, P.J.1
Dent, J.2
Lauritsen, K.3
-
18
-
-
0025633361
-
Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk
-
Farrington CP, Manning G,. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med 1990; 9: 1447-54.
-
(1990)
Stat Med
, vol.9
, pp. 1447-1454
-
-
Farrington, C.P.1
Manning, G.2
-
19
-
-
28144433010
-
Potassium-competitive acid blockade: A new therapeutic strategy in acid-related diseases
-
Andersson K, Carlsson E,. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther 2005; 108: 294-307.
-
(2005)
Pharmacol Ther
, vol.108
, pp. 294-307
-
-
Andersson, K.1
Carlsson, E.2
-
20
-
-
84882756075
-
Efficacy and safety of esomeprazole, compared with omeprazole, in maintenance therapy for reflux esophagitis - A phase III, multicenter, randomized, double-blind trial
-
Kinoshita Y, Miwa H, Kasugai K,. Efficacy and safety of esomeprazole, compared with omeprazole, in maintenance therapy for reflux esophagitis-a phase III, multicenter, randomized, double-blind trial. Nihon Shokakibyo Gakkai Zasshi 2013; 110: 1428-38.
-
(2013)
Nihon Shokakibyo Gakkai Zasshi
, vol.110
, pp. 1428-1438
-
-
Kinoshita, Y.1
Miwa, H.2
Kasugai, K.3
|